Zobrazeno 1 - 10
of 136
pro vyhledávání: '"John S, Kauh"'
Autor:
R. Donald Harvey, Bruce J. Dezube, George Mulligan, Kristine Burke, Allison J. Berger, Hélène M. Faessel, Michael D. Pickard, Devalingam Mahalingam, James M. Cleary, Glen J. Weiss, John S. Kauh, Jeffrey W. Clark, Roger B. Cohen, Geoffrey I. Shapiro, John Sarantopoulos
Supplemental Table 1: Treatment-related AEs experienced by {greater than or equal to}10% of patients on any schedule, and treatmentrelated grade {greater than or equal to}3 AEs reported in at least 1 patient; Supplemental Table 2: Summary of hepatoto
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::75456e92ff982140d74cb102fe174526
https://doi.org/10.1158/1078-0432.22460184.v1
https://doi.org/10.1158/1078-0432.22460184.v1
Autor:
R. Donald Harvey, Bruce J. Dezube, George Mulligan, Kristine Burke, Allison J. Berger, Hélène M. Faessel, Michael D. Pickard, Devalingam Mahalingam, James M. Cleary, Glen J. Weiss, John S. Kauh, Jeffrey W. Clark, Roger B. Cohen, Geoffrey I. Shapiro, John Sarantopoulos
Purpose: To determine the dose-limiting toxicities (DLTs) and maximum tolerated dose (MTD) of the investigational NEDD8-activating enzyme (NAE) inhibitor pevonedistat (TAK-924/MLN4924) and to investigate pevonedistat pharmacokinetics and pharmacodyna
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30f76b5b4dc66d7673263c84e4919004
https://doi.org/10.1158/1078-0432.c.6524421.v1
https://doi.org/10.1158/1078-0432.c.6524421.v1
Autor:
R. Donald Harvey, Bruce J. Dezube, George Mulligan, Kristine Burke, Allison J. Berger, Hélène M. Faessel, Michael D. Pickard, Devalingam Mahalingam, James M. Cleary, Glen J. Weiss, John S. Kauh, Jeffrey W. Clark, Roger B. Cohen, Geoffrey I. Shapiro, John Sarantopoulos
Individual dose-normalized exposures of pevonedistat (as assessed by Cmax and AUC24) obtained on Day 1 and Day 5 for schedule B (with dexamethasone) and schedule C (without dexamethasone).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::acef34629e04fb77315450ae17a00a1d
https://doi.org/10.1158/1078-0432.22460187
https://doi.org/10.1158/1078-0432.22460187
Autor:
MD Jennifer R. Eads, MD Satya Das, MD Daneng Li, MD Amr Mohamed, MBS, CCRP Christopher Tucci, MS Shivani Nanda, MD, FACP John S. Kauh, MD, MBA Marek K. Kania, MD Arvind Dasari
Publikováno v:
Endocrine Abstracts.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::133fb1c7ba28815bd976836b370f113a
https://doi.org/10.1530/endoabs.89.c6
https://doi.org/10.1530/endoabs.89.c6
Autor:
Sonya C. Chapman, Michelle Carlsen, Robert Wesolowski, Omid Hamid, Richard D. Carvajal, R. Donald Harvey, Daniel A. Peterson, Afshin Dowlati, Anna M. Szpurka, Danni Yu, John S. Kauh, Samuel J. Klempner, Tonya Quinlan
Publikováno v:
Investigational New Drugs. 39:1057-1071
Background Tumor-associated macrophages (TAMs) promote tumor growth, metastasis, and therapeutic resistance via colony-stimulating factor-1 (CSF-1), acting through CSF-1 receptor (CSF-1R) signaling. This phase 1 study determined the safety, tolerabil
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::457ed899095e312b897d27066d988821
https://doi.org/10.1007/s10637-021-01084-8
https://doi.org/10.1007/s10637-021-01084-8
Autor:
Daniel C. Danila, Thompson N. Doman, Jonathan Landa, David Schaer, Shanu Modi, Elizabeth A. Comen, Matthew Adamow, Jill S. Gluskin, Susan F. Slovin, Michael J. Morris, Suhyun Kang, Manisha Brahmachary, Sonya C. Chapman, David M. J. Hoffman, Rachel Sanford, Jeremy C. Durack, Josef J. Fox, Michelle Carlsen, Ruslan D. Novosiadly, Philomena McAndrew, John S. Kauh, Dana E. Rathkopf, Courtney M. Tate, Danni Yu, Karen A. Autio, Victoria S. Blinder, Phillip Wong, Praneet Kang, Christopher A. Klebanoff, Heather L. McArthur
Publikováno v:
Clin Cancer Res
Purpose: Tumor-associated macrophages correlate with increased invasiveness, growth, and immunosuppression. Activation of the colony-stimulating factor-1 receptor (CSF-1R) results in proliferation, differentiation, and migration of monocytes/macropha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::448fc06501a6592a9a8ac8ca34449998
https://doi.org/10.1158/1078-0432.ccr-20-0855
https://doi.org/10.1158/1078-0432.ccr-20-0855
Autor:
Paul J. Catalano, Thomas J. George, Joel N. Saltzman, Jeffrey Zangmeister, Elena G. Chiorean, Al B. Benson, Peter J. O'Dwyer, Neal J. Meropol, Puneet S. Cheema, John S. Kauh, Jean L. Grem, Michael J. Hall, Yang Feng, Mary F. Mulcahy
Publikováno v:
Cancer. 124:688-697
Background The authors hypothesized that patients with metastatic colorectal cancer (mCRC) who had tumors with low thymidylate synthase (TS-L) expression would have a higher response rate to combined 5-fluorouracil, leucovorin, and oxaliplatin (FOLFO
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::36f4b76b9ca4c6b76a8f5f47cc7bd903
https://doi.org/10.1002/cncr.30967
https://doi.org/10.1002/cncr.30967
Autor:
Denise A. Yardley, Mohamad Adham Salkeni, Linda T. Vahdat, Ling Gao, William J. Gradishar, Shande Tang, Kathy D. Miller, John S. Kauh, Patrick J. Ward, Gladys Rodriguez, Agustin A. Garcia, Anil A. Joy, Joseph A. Sparano, Rachel M. Layman, James Khatcheressian, Rita P. Dalal
Publikováno v:
The Oncologist. 22:245-254
Background Icrucumab (ICR) and ramucirumab (RAM) bind vascular endothelial growth factor (VEGF) receptors 1 and 2 (VEGFR-1 and -2), respectively. This open-label, randomized phase II study evaluated their efficacy and safety in combination with capec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ffdf79c7a867fa46734f13fca82474d1
https://doi.org/10.1634/theoncologist.2016-0265
https://doi.org/10.1634/theoncologist.2016-0265
Autor:
John S. Kauh, Shivani Nanda, Andrew Scott Paulson, Arvind Dasari, Marek K. Kania, Jennifer W Carlisle, Christopher Tucci
Publikováno v:
Journal of Clinical Oncology. 39:TPS2677-TPS2677
TPS2677 Background: Surufatinib (S) is an inhibitor of VEGFR1, 2, & 3; FGFR1; and CSF-1R. In two phase 3 randomized trials (SANET-ep; NCT02588170 & SANET-p; NCT02589821) S demonstrated a manageable safety profile and statistically significant efficac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::04b844ee980487c7530df99f920b051c
https://doi.org/10.1200/jco.2021.39.15_suppl.tps2677
https://doi.org/10.1200/jco.2021.39.15_suppl.tps2677
Autor:
Shivani Nanda, Daneng Li, Christopher Tucci, Arvind Dasari, Andrew Scott Paulson, Max W. Sung, Marek K. Kania, John S. Kauh
Publikováno v:
Journal of Clinical Oncology. 39:4114-4114
4114 Background: Surufatinib (S) is a targeted inhibitor of tyrosine kinases VEGFR1, 2, and 3; FGFR1; and CSF-1R. A manageable safety profile and statistically significant efficacy of S have previously been demonstrated in patients (pts) with advance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a7ca4af7e215aa8082692dbcec983d9c
https://doi.org/10.1200/jco.2021.39.15_suppl.4114
https://doi.org/10.1200/jco.2021.39.15_suppl.4114